Show results for
Refine by
Lymphoma Equipment & Supplies In Cuba
148 equipment items found
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Bortezomib (brand name: Velcade) is a treatment for multiple myeloma (a cancer of the plasma cells) and mantle cell lymphoma (a cancer of the lymph ...
Manufactured by:Antengene Corporation Limited based inChangning District, CHINA
Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) in adults and a highly heterogeneous malignancy in both clinical manifestations and prognosis. DLBCL accounts for 30%-40% of all NHL cases, and over 40% in most Asian ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy. The epitopes recognized by HLA-DR are not shed or internalized, enabling stable binding to human lymphoma cells. MVR CAR-T can also be used in patients who relapse after CD19 CAR-T treatment. Reduction of cytokine secretion due to selective killing of tumor ...
Manufactured by:Medax Srl based inSan Possidonio (MO), ITALY
Patented rectangular shaped cannula. 4 mm wide flat biopsy sample. Ultrasharp stylet tip clearly visible with ultrasound guidance. Adjustable penetration depth 12/22 mm. Centimeter markings. Ergonomic handle. Easy sample retrieval and release. Sterilized by ETO, shelf life 5 ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Brentuximab vedotin (brand name: Adcetris) is a treatment for post-transplant consolidation, relapsed or refractory Hodgkin lymphoma (cancer of the lymphatic system distinguished by the presence of CD30-positive Reed-Sternberg cells), and systemic anaplastic large cell lymphoma (a type of aggressive T-cell ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been ...
Manufactured by:Caprico Biotechnologies, Inc. (CBI) based inNorcross, GEORGIA (US) (USA)
The L243 reacts with human HLA-DR antigen which is expressed on B lymphocytes, monocytes, macrophages, activated T lymphocytes, activated natural killer (NK) lymphocytes, and human progenitor cells. HLA-DR is also present on thymic epithelium, B lymphocyte dependent areas of spleen and lymph node, and B cell ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB003 is an allogeneic CAR-T product using engineered GDTs from healthy donors and specifically targets CD19, which is highly expressed on a number of B cell malignancies. These malignancies, such as acute lymphoblastic Leukaemia (ALL) or diffuse large B cell lymphoma (DLBCL) arise when B cells replicate uncontrollably within the bone marrow, before progressing to the ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,4 showed antitumor responses in a Phase 1/2 trial as a monotherapy in 15 patients with T-cell lymphomas and cutaneous involvement (44% ORR).5 When ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). ...
Manufactured by:Enterome based inParis, FRANCE
The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in indolent non-Hodgkin lymphoma (iNHL). EO2463 is being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with standard-of-care lenalidomide and/or rituximab for the treatment of iNHL (SIDNEY study, EONHL1-20). ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has been approved by the NMPA for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis for which the originator ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma ...
Manufactured by:Novodiax, Inc. based inHayward, CALIFORNIA (USA)
Anti-CD45 antibody is a useful tool for identifying tumor cells of lymphoid origin. It is routinely used to aid the differential diagnosis of undifferentiated neoplasms, whenever malignant lymphoma is suspected by morphologic clinical data. CD45 is a Type I trans-membrane protein which is in various forms present on all differentiated hematopoietic cells except erythrocytes and ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within cancer cells to inhibit their growth and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg dose in a lymphoma study and with a ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity[1][2]. Elimusertib can be used for the research of solid tumors and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and ...